Alexa Siddon

Alexa Siddon, MD, is an Assistant Professor in the Department of Laboratory Medicine at Yale School of Medicine, with secondary appointments in Pathology. She serves as Hematopathology Fellowship Director, Director of the Molecular Diagnostics Laboratory, Director of Flow Cytometry, and Associate Director of the Hematology Laboratory. She is also affiliated with the Yale Cancer Center, Clinical Flow Cytometry Laboratory, and the Hematopathology Laboratory at the Veteran Affairs Connecticut Healthcare System.

Dr. Siddon's research focuses on hematopathology, particularly myeloid malignancies, acute leukemias, and post-transplant monitoring. Her work integrates molecular diagnostics, flow cytometry, and genomic analysis to improve patient diagnosis and outcomes. She has co-authored over 10 peer-reviewed articles in recent years, frequently collaborating with leading hematologists and pathologists such as Christopher Tormey, Henry Rinder, and Rory Shallis.

Her publications reveal a strong trend in translational research, emphasizing the clinical implications of genetic mutations (e.g., TP53, NPM1, IDH1/2), chimerism testing post-transplant, and immunophenotypic characterization of hematologic malignancies. The research spans disciplines including oncology, molecular biology, immunology, and clinical pathology, with a clear focus on precision diagnostics and prognostic modeling.

Scientific Awards:

• ASCP Distinguished Educator Award
• Paul J. Strandjord Young Investigator Award
• Donald H. Buchholz Research Prize

Dr. Siddon is actively involved in medical education, directing fellowship programs and mentoring trainees. She has no reported grants listed in the text, but her leadership in diagnostic laboratories and active publication record suggest ongoing research funding. She is not part-time, not retired, and remains a current, active faculty member.

She is affiliated with multiple research entities including the Cancer Immunology Center, Center for Biomedical Data Science, and the Yale Cancer Center, contributing to interdisciplinary teams focused on hematologic malignancies and diagnostic innovation.